These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 37344934)
21. Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes. Thompson KM; Duintjer Tebbens RJ J Infect Dis; 2017 Jul; 216(suppl_1):S168-S175. PubMed ID: 28838198 [TBL] [Abstract][Full Text] [Related]
22. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036. Thompson KM; Kalkowska DA; Badizadegan K Expert Rev Vaccines; 2022 Nov; 21(11):1667-1674. PubMed ID: 36154436 [TBL] [Abstract][Full Text] [Related]
23. Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan. Kalkowska DA; Thompson KM Risk Anal; 2021 Feb; 41(2):266-272. PubMed ID: 32144841 [TBL] [Abstract][Full Text] [Related]
24. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). Thompson KM; Kalkowska DA Expert Rev Vaccines; 2019 Jul; 18(7):725-736. PubMed ID: 31248293 [No Abstract] [Full Text] [Related]
29. Potential Future Use, Costs, and Value of Poliovirus Vaccines. Thompson KM; Kalkowska DA Risk Anal; 2021 Feb; 41(2):349-363. PubMed ID: 32645244 [TBL] [Abstract][Full Text] [Related]
30. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016. Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D; MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675 [TBL] [Abstract][Full Text] [Related]
31. Polio endgame: the global introduction of inactivated polio vaccine. Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843 [TBL] [Abstract][Full Text] [Related]
32. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses. Thompson KM; Kalkowska DA; Duintjer Tebbens RJ Vaccine; 2015 Mar; 33(13):1568-77. PubMed ID: 25701673 [TBL] [Abstract][Full Text] [Related]
33. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272 [TBL] [Abstract][Full Text] [Related]